FocalTherics (NASDAQ:FOCL) Director Acquires $237,500.00 in Stock

FocalTherics (NASDAQ:FOCL) Director Lance Willsey acquired 50,000 shares of the firm’s stock in a transaction dated Friday, August 14th. The stock was bought at an average price of $4.75 per share, for a total transaction of $237,500.00. Following the acquisition, the director owned 1,291,780 shares of the company’s stock, valued at approximately $6,135,955. This trade represents a 4.03% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link.

FocalTherics Trading Up 2.3%

NASDAQ FOCL opened at $4.36 on Thursday. The company has a market cap of $163.41 million, a price-to-earnings ratio of -4.23 and a beta of -0.04. FocalTherics has a 1-year low of $1.30 and a 1-year high of $6.40. The firm has a 50-day moving average of $5.37. The company has a debt-to-equity ratio of 1.79, a quick ratio of 0.99 and a current ratio of 1.60.

FocalTherics (NASDAQ:FOCL) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.19). FocalTherics had a negative return on equity of 248.00% and a negative net margin of 56.26%.The company had revenue of $13.20 million during the quarter. As a group, equities research analysts forecast that FocalTherics will post -0.78 earnings per share for the current fiscal year.

Institutional Investors Weigh In On FocalTherics

Several institutional investors and hedge funds have recently modified their holdings of FOCL. Rock Springs Capital Management LP boosted its stake in shares of FocalTherics by 7.1% during the 1st quarter. Rock Springs Capital Management LP now owns 1,378,000 shares of the company’s stock valued at $5,126,000 after purchasing an additional 91,500 shares in the last quarter. Lido Advisors LLC bought a new position in FocalTherics in the first quarter worth about $40,000. SmartHarvest Portfolios LLC purchased a new stake in FocalTherics in the first quarter worth about $38,000. Flax Pond Capital LLC purchased a new stake in FocalTherics in the fourth quarter worth about $2,623,000. Finally, Kovack Advisors Inc. bought a new stake in FocalTherics during the 4th quarter valued at approximately $53,000. 62.74% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Piper Sandler reiterated a “neutral” rating and set a $4.00 price target on shares of FocalTherics in a report on Friday, August 14th. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of FocalTherics in a research report on Tuesday, June 2nd. Wall Street Zen lowered shares of FocalTherics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Mizuho set a $15.00 target price on shares of FocalTherics and gave the stock an “outperform” rating in a report on Friday, July 17th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of FocalTherics in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, FocalTherics presently has an average rating of “Hold” and an average target price of $7.75.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.